848084-84-4
Chemical Structure
Tigapotide TFA
Synonym(s): PCK 3145 TFA
- CAS No.: 848084-84-4
- Formula:C84H120F3N21O36S3
- Molecular Weight:2153.17
IUPAC Name: (2S,5S,8S,11R,14S,17R,20S,23S,26R,29S,32S,35S,38S,41S,44S)-41-((1H-indol-3-yl)methyl)-11,17,26-tris(((acetamidomethyl)thio)methyl)-44-amino-29-(2-amino-2-oxoethyl)-38-(3-amino-3-oxopropyl)-5,23-bis(2-carboxyethyl)-32-(carboxymethyl)-8-(4-hydroxybenzyl)-2,14,20,35-tetrakis((R)-1-hydroxyethyl)-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecaazaheptatetracontanedioic acid compound with 2,2,2-trifluoroacetic acid (1:1)
SMILES: C(C(O)=O)(F)(F)F.C([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@H](C(N[C@@H]([C@@H](C)O)C(O)=O)=O)CCC(O)=O)=O)=O)CSCNC(C)=O)=O)[C@@H](C)O)=O)CSCNC(C)=O)=O)[C@@H](C)O)=O)CCC(O)=O)=O)CSCNC(C)=O)=O)CC(N)=O)=O)CC(O)=O)=O)[C@@H](C)O)=O)CCC(N)=O)=O)NC([C@H](CCC(O)=O)N)=O)C=2C=3C(NC2)=CC=CC3
Biological Activity: Tigapotide TFA (PCK-3145 TFA) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide TFA inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide TFA induces Apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide TFA inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide TFA reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide TFA is applicable for the research of prostate cancer and malignancy-associated hypercalcemia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tigapotide TFA | Tigapotide TFA (PCK-3145 TFA) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide TFA inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide TFA induces Apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide TFA inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide TFA reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide TFA is applicable for the research of prostate cancer and malignancy-associated hypercalcemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pippa, N., et al. Advanced nanocarriers for an antitumor peptide. J Nanopart Res 15, 2062 (2013).
- [2]. Shukeir N, et al. Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs. 2005;16(10):1045-1051. [Content Brief]
